ENLIVEN THERAPEUTICS, INC. Announced positive proof of concept data from Phase 1 clinical trial of ELVN-001 in CML, achieving an initial cumulative MMR rate of 44% (7/16) by 12 weeks in response-evaluable patients
Strong balance sheet with
“The first quarter of 2024 was a pivotal quarter for Enliven. We released positive proof of concept data from our Phase 1 clinical trial of ELVN-001, which was a significant milestone for the Company,” said
Corporate Updates
- Entered into a securities purchase agreement for a private investment in public equity (PIPE) financing resulting in gross proceeds of
$90 million . The financing, from both new and existing investors, is expected to extend the Company’s cash runway into late 2026 and through multiple key milestones for ELVN-001 and ELVN-002. - Appointed to the Board of Directors,
Lori Kunkel , MD, an accomplished industry executive and board member with a track record of success in corporate strategy, clinical development and commercialization.
Pipeline Updates
ELVN-001 is a potent, highly selective, potentially best-in-class small molecule kinase inhibitor designed to specifically target the BCR-ABL gene fusion, the oncogenic driver for patients with chronic myeloid leukemia (CML).
- Announced positive proof of concept data from the Phase 1 clinical trial evaluating ELVN-001 in patients with CML who are relapsed, refractory or intolerant to available tyrosine kinase inhibitors (TKIs).
- As of the cutoff date of
March 18, 2024 , 44% (7/16) of response-evaluable patients achieved a cumulative major molecular response (MMR) rate by week 12, and patients with prior exposure to asciminib and/or who were TKI-resistant also demonstrated responses, with a 44% and 40% cumulative MMR rate, respectively. Among response-evaluable patients, all had improved or stable BCR::ABL1 transcript levels by 12 weeks. ELVN-001 was well tolerated with no Grade 3 or higher non-hematologic treatment-related adverse events and no dose reductions reported. - These data compare favorably to precedent Phase 1 cumulative MMR rates for approved BCR::ABL1 TKIs, particularly given the more heavily pre-treated patient population. Further details can be found here.
- Phase 1b data is expected in 2025 and is expected to include between approximately 60-100 patients across various lines of therapy with significant follow-up.
- As of the cutoff date of
ELVN-002 is a potent, highly selective, central nervous system penetrant and irreversible HER2 inhibitor with activity against wild type HER2 and various HER2 mutations.
- Following
U.S. Food and Drug Administration approval of its Investigational New Drug application, the Company activated the first site to evaluate ELVN-002 in combination with trastuzumab +/- chemotherapeutic agents in HER2+ metastatic breast cancer (MBC) and colorectal cancer (CRC). First patient dosing for the combination trial is expected in Q2 2024. - The combination trial in patients with HER2+ cancers is supported by the initial data from the ongoing monotherapy trial, which includes:
- Investigator reported responses (including unconfirmed) in both HER2+ and HER2 mutant tumors, including in patients who have progressed on Enhertu and patients with brain metastases, at doses that have been well tolerated.
- Importantly, at the clinically predicted optimal monotherapy dose, ELVN-002 had >10x target coverage based on pharmacokinetics in cancer patients and preclinical HER2+ efficacy compared to tucatinib.
- Phase 1 monotherapy data, Phase 1a/b Herceptin combination data in HER2+ CRC, and initial Phase 1a combination data in HER2+ MBC are expected in 2025.
First Quarter 2024 Financial Results
- Cash Position: As of
March 31, 2024 , the Company had cash, cash equivalents and marketable securities totaling$320.5 million , which is expected to provide cash runway into late 2026. - Research and development (R&D) expenses: R&D expenses were
$20.0 million for the first quarter of 2024, compared to$11.9 million for the first quarter of 2023. - General and administrative (G&A) expenses: G&A expenses for the first quarter of 2024 were
$6.0 million , compared to$4.5 million for the first quarter of 2023. - Net Loss: Enliven reported a net loss of
$22.7 million for the first quarter of 2024, compared to a net loss of$14.7 million for the first quarter of 2023.
About Enliven Therapeutics
Enliven Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule inhibitors to help people with cancer not only live longer, but live better. Enliven aims to address existing and emerging unmet needs with a precision oncology approach that improves survival and enhances overall well-being. Enliven’s discovery process combines deep insights in clinically validated biological targets and differentiated chemistry to design potentially first-in-class or best-in-class therapies. Enliven is based in
Forward-Looking Statements
This press release contains forward-looking statements (including within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended) concerning Enliven and other matters. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the management of Enliven, as well as assumptions made by, and information currently available to, management of Enliven. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “would,” “expect,” “anticipate,” “plan,” “likely,” “believe,” “estimate,” “project,” “intend,” and other similar expressions or the negative or plural of these words, or other similar expressions that are predictions or indicate future events or prospects, although not all forward-looking statements contain these words. Statements that are not historical facts are forward-looking statements. Forward-looking statements in this press release include, but are not limited to, statements regarding the potential of, and plans and expectations regarding Enliven’s programs, including ELVN-001 and ELVN-002; Enliven’s pipeline of product candidates; expected milestones for ELVN-001 and ELVN-002, including the expected timing of dosing of ELVN-002 for the combination trial and of data from the clinical trials of ELVN-001 and ELVN-002; statements relating to Enliven’s expected cash runway; and the anticipated use of proceeds from the PIPE financing; and statements by Enliven’s Co-founder and Chief Executive Officer. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various risks and uncertainties, including, without limitation: the limited operating history of Enliven; the ability to advance product candidates through preclinical and clinical development; the ability to obtain regulatory approval for, and ultimately commercialize, product candidates; the outcome of preclinical testing and early clinical trials for product candidates and the potential that the outcome of preclinical testing and early clinical trials may not be predictive of the success of later clinical trials; Enliven’s limited resources; the risk of failing to demonstrate safety and efficacy of product candidates; Enliven’s limited experience as a company in designing and conducting clinical trials; the potential for interim, topline and preliminary data from Enliven’s preclinical studies and clinical trials to materially change from the final data; potential delays or difficulties in the enrollment or maintenance of patients in clinical trials; developments relating to Enliven’s competitors and its industry, including competing product candidates and therapies; the decision to develop or seek strategic collaborations to develop Enliven’s current or future product candidates in combination with other therapies and the cost of combination therapies; the ability to attract, hire, and retain highly skilled executive officers and employees; the ability of Enliven to protect its intellectual property and proprietary technologies; the scope of any patent protection Enliven obtains or the loss of any of Enliven’s patent protection; reliance on third parties, including contract manufacturing organizations, contract research organizations and strategic partners; general market or macroeconomic conditions; Enliven’s ability to obtain additional capital to fund Enliven’s general corporate activities and to fund Enliven’s research and development; and other risks and uncertainties, including those more fully described in Enliven’s filings with the
Head-to-Head Comparisons
The Company has not performed any head-to-head trials for ELVN-001. As a result, the data referenced in this press release is derived from different clinical trials at different points in time, with differences in trial design and patient populations. As a result, conclusions from cross-trial comparisons cannot be made.
Contact:
Investors
ir@enliventherapeutics.com
Media
media@enliventherapeutics.com
| Selected Condensed Consolidated Financial Information | |||||||
| (in thousands, except per share data) | |||||||
| (unaudited) | |||||||
| Statements of Operations | Three Months Ended | ||||||
| 2024 | 2023 | ||||||
| Operating expenses: | |||||||
| Research and development | $ | 19,970 | $ | 11,880 | |||
| General and administrative | 6,017 | 4,538 | |||||
| Total operating expenses | 25,987 | 16,418 | |||||
| Loss from operations | (25,987 | ) | (16,418 | ) | |||
| Other income (expense), net | 3,249 | 1,694 | |||||
| Net loss | $ | (22,738 | ) | $ | (14,724 | ) | |
| Net loss per share, basic and diluted | $ | (0.54 | ) | $ | (0.80 | ) | |
| Weighted-average shares outstanding, basic and diluted | 42,046 | 18,515 | |||||
| Balance Sheets | |||||||
| 2024 | 2023 | ||||||
| Assets | |||||||
| Current assets: | |||||||
| Cash, cash equivalents and marketable securities | $ | 320,504 | $ | 253,148 | |||
| Restricted cash | 54 | 54 | |||||
| Prepaid expenses and other current assets | 6,641 | 2,949 | |||||
| Contingent value right asset | 10,000 | 10,000 | |||||
| Total current assets | 337,199 | 266,151 | |||||
| Property and equipment, net | 683 | 742 | |||||
| Operating lease right-of-use assets | 241 | 320 | |||||
| Deferred offering costs | 563 | 563 | |||||
| Other long-term assets | 4,091 | 4,091 | |||||
| Total assets | $ | 342,777 | $ | 271,867 | |||
| Liabilities and Stockholders' Equity | |||||||
| Current liabilities: | |||||||
| Accounts payable | $ | 2,727 | $ | 532 | |||
| Accrued expenses and other current liabilities | 12,304 | 15,362 | |||||
| Contingent value right liability | 10,000 | 10,000 | |||||
| Total current liabilities | 25,031 | 25,894 | |||||
| Long-term liabilities | 34 | 67 | |||||
| Total liabilities | 25,065 | 25,961 | |||||
| Stockholders' equity | 317,712 | 245,906 | |||||
| Total liabilities and stockholders' equity | $ | 342,777 | $ | 271,867 | |||
2024 GlobeNewswire, Inc., source
